Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2

B-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Kunwar, Gollapudi, Sumanth, Mittal, Sasha, Small, Corinn, Kumar, Jyoti, Ohgami, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065453/
https://www.ncbi.nlm.nih.gov/pubmed/33801781
http://dx.doi.org/10.3390/diagnostics11040600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065453/
https://www.ncbi.nlm.nih.gov/pubmed/33801781
http://dx.doi.org/10.3390/diagnostics11040600

Ejemplares similares